A case-control study was conducted to determine the association between plasma organochlorine levels and prostate cancer risk. Male clinic patients scheduled for prostate core biopsy or seeing their urologist for other conditions from 1997 through 1999 in Kingston, Ontario were eligible, excluding those with an earlier cancer. Age frequency matched controls (n ¼ 329) were compared with 79 incident prostate cancer cases. Before knowledge of diagnosis, the patients completed a questionnaire and donated 15 ml of blood for the measurement of 14 PCBs, and 13 organochlorine pesticides by gas chromatography. At least 70% of patients had detectable levels of nine PCB congeners and seven pesticides, and these chemicals were included in the risk analysis adjusted for total lipids. Geometric means for these PCB congeners, total PCBs, and p,p'-DDE are slightly lower for cases than controls, whereas the levels of p,p'-DDT and other pesticides are virtually equal. Adjusting for age and other confounders in multivariable logistic regression, odds ratios (ORs) are consistently below 1.0 for PCB congeners and total PCBs. For pesticides, most ORs are very close to the null. This study suggests that longterm low-level exposure to organochlorine pesticides and PCBs in the general population does not contribute to increased prostate cancer risk.
Introduction
Although prostate cancer is the most commonly diagnosed cancer among men in North America, its etiology is poorly understood (Bostwick et al., 2004) . About 10% of prostate cancer cases can be attributed to genetic factors (Carter et al., 1993; Whittemore et al., 1995a, b; Lesko et al., 1996; Rodriguez et al., 1997; Cerhan et al., 1999; Stanford and Ostrander, 2003) , and environmental risk factors, such as lifestyle, vasectomy, medical history, occupational, and dietary factors, have come under scrutiny as well (Whittemore et al., 1995a, b; Gann et al., 1996; Kolonel, 1996; Clinton and Giovannucci, 1998; Hsieh et al., 1998; Hayes et al., 1999) . Although it is biologically plausible that some environmental chemicals that have been labeled as known or suspected human carcinogens may contribute to prostate cancer risk through a direct carcinogenic mechanism such as DNA damage (WHO, 1997 (WHO, , 1998 , rarely have they been assessed in studies using biomarkers. Another route to prostate cancer may be through an indirect mechanism where xenoestrogens or environmental androgens interfere with endogenous hormones (Sonnenschein and Soto, 1998) , plausible as the prostate is hormonally dependent for its growth and function.
Various studies have suggested that exposure to some pesticides and agricultural chemicals may increase cancer risk, but in most the associations are tenuous and inconsistent (Ritchie et al., 2003; Rogan and Chen, 2005) . Indirect evidence of a potential effect of organochlorines on prostate cancer risk, in particular, comes from several epidemiological studies identifying elevated risk among farm workers and pesticide applicators (Forastiere et al., 1993; Van Der Gulden and Vogelzang, 1996; Band et al., 1999; Cerhan et al., 1999; Fleming et al., 1999; Schreinemachers et al., 1999; SharmaWagner et al., 2000; Settimi et al., 2001 Settimi et al., , 2003 Meyer et al., 2007) , as well as through non-occupational exposure to pesticides (Sharpe et al., 2001) . To evaluate the association between plasma concentrations of several persistent organochlorines and prostate cancer, a case-control study of men visiting urology clinics was conducted using a sensitive measurement method and adjusting for total lipids in plasma.
Materials and methods

Patient Accrual
All men aged 50-80 years who had visited one of a group of five urologists from 1997 to 1999 in Kingston, Ontario were eligible. Of 1288 men seen in clinic, 746 were excluded for one of the following reasons: earlier diagnosis of prostate cancer, too ill as determined by their physician, missing prostate-specific antigen (PSA) measurements, suspected prostate cancer because of abnormal digital rectal examination (DRE) or PSA measurements among controls (i.e., PSAZ3.5 in 50-60 age group, PSAZ4.5 in 60-70 age group or PSAZ6.5 in 70-80 age group) but without a prostate biopsy to give a definitive diagnosis, missing dates for DRE or PSA tests, or a difference of greater than 1 year between DRE or PSA test date and clinic date.
Of the 542 patients eligible by these criteria, 56 refused to participate (9.0% of cases and 10.6% of controls) (see Figure 1 ). In addition, 78 were excluded due to a diagnosis of prostate intraepithelial neoplasia (PIN) (n ¼ 25), use of hormonal medications (Andriol, Bromocriptine, Delatestryl, Testosterone, Spironolactone, Flutamide, Parlodel, Aldactone, Metandren) (n ¼ 18), or having not provided a blood sample (n ¼ 35). Consequently, 408 study participants had complete organochlorine and questionnaire data. Of these, 194 participants did not require a biopsy and were designated ''urology controls'' and 214 participants who were suspected of having prostate carcinoma underwent prostate core biopsies. This biopsy was usually a standard six-core transrectal ultrasound-guided biopsy, taking samples from various areas of the prostate, with additional samples from any area where an abnormality was noted on the ultrasound. Of the 214 patients having a biopsy, 79 were diagnosed with incident primary prostate cancer (''cases''), whereas the remaining 135 patients in whom no cancer was found were classified as ''biopsy controls''. The urology controls were age frequency matched to cases to within a 5-year age range, and were diagnosed with one or more of the following conditions: erectile dysfunction (n ¼ 54), prostatitis (n ¼ 27), benign prostatic hyperplasia (BPH) (n ¼ 38), hematospermia/hematuria (n ¼ 14), urinary obstruction/ urgency/nocturia (n ¼ 14), other infection/pain in urinary organs (n ¼ 14), or renal calculi (n ¼ 12), plus 29 with PSA/ DRE normal screening but with several other urology conditions. All of these urology controls were confirmed with normal DRE and PSA tests, and were included because they were known to be cancer-free and were able to provide a blood sample. Therefore, a total of 329 controls were included in the study.
Procedures
Participating men were asked to donate 15 ml of blood for analyses of lipids and organochlorines. Patients were also given a questionnaire to complete at home and then were contacted by telephone to record responses. The interview was conducted generally before knowledge of biopsy results, and the interviewer was always unaware of case-control status. The questionnaire included information on demographics, weight at the age of 40 years, height, medical history, use of hormone medication, use of vitamin or mineral supplements, family history of prostate and breast cancer, surrogates of early life hormonal exposures, physical activity as a teen, occupation, and food frequency to record the consumption of 67 foods 2 years before interview.
Biomarker Measurements
Chemical analyses included 14 PCB congeners (PCB28, PCB52, PCB99, PCB101, PCB105, PCB118, PCB128, PCB138, PCB153, PCB156, PCB170, PCB180, PCB183, and PCB187) and 13 pesticides (aldrin, b-hexachlorocyclohexane, a-chlordane, g-chlordane, cis-nonachlor, p,p'-DDE, p,p'-DDT, dieldrin, heptachlorepoxide, hexachlorobenzene, mirex, oxychlordane, and trans-nonachlor). Most of these PCB congeners are mixed-type inducers that have been reported frequently in the environmental samples (McFarland and Clarke, 1989) . For determination of organochlorines, 2 ml of blood plasma were extracted, cleaned on Florisil columns, and fraction 1 and fraction 2 were eluted. For gas chromatography, fractions were evaporated and dissolved, and lipids were precipitated at À201C. After centrifugation, the fractions and the lipids were taken to a final volume of 100 ml and analyzed on an HP-5890 series II gas chromatograph with dual capillary columns and dual Ni-63 electroncapture detectors 35 . Peaks were identified by their relative retention times obtained on the two columns, using a computer program developed in-house. The identification window was ± 0.001, and quantification was mainly carried out on the Ultra-1 column. Three calibration standards were used for each batch of samples. A hexane non-extracted standard containing PCB congeners and pesticides at 0.5 mg/l was used to check columns performance and detectors sensitivity. A water extract standard containing PCB congeners and pesticides except p,p'-DDT at 0.5 mg/l was used to calculate the calibration curve for PCBs and pesticides except aldrin, p,p'-DDT, b-hexachlorocyclohexane, and hexachlorobenzene. A plasma extract standard containing PCB congeners and pesticides with p,p'-DDT at 0.5 mg/l was used to calculate the calibration curve for p,p'-DDT, b-hexachlorocyclohexane, and hexachlorobenzene.
Total lipid in plasma was determined in 5 ml by a ''summation'' method, in which total cholesterol (TC), free cholesterol (FC), triglycerides (TG), and phospholipids (PL) were individually measured with an enzymatic method, then summed to obtain a total plasma lipid value. Total cholesterol and triglycerides were determined in duplicate, using enzymatic methods, with the DuPont automatic clinical analyzer (ACA III) (DuPont, Wilmington, DE, USA) and the ACA cholesterol and triglyceride test packs. ''Free'' (non-esterified) cholesterol was measured in duplicate by the Wako Phospholipids B enzymatic method (phospholipase D and choline oxidase) (Wako Chemicals USA Inc., Richmond, VA, USA), which was adapted to the Abbott Analyzer (Global Medical Instrumentation Inc., Albertville, Minnesota, USA). Plasma total lipid was calculated from the expression: TL ¼ 1.677 (TC-FC) þ FC þ TG þ PL. The constant 1.677 is a factor derived from the ratio of the mean molecular weight of plasma cholesterol esters to the molecular weight of cholesterol and was included to correct for the weight of fatty acids in the cholesterol ester fraction.
The measurement unit of the organochlorine results (mg/l) was transformed to mg/kg lipid using total lipid values calculated, based on the method used by Phillips et al. (1989) . Detection limits, based on three times the average SD were as follows: 4.0 mg/kg lipid for PCB congeners; 8.0 mg/kg lipid for p,p'-DDT and b-hexachlorocyclohexane; 20 mg/kg lipid for dieldrin and heptachlorepoxide; and 4.0 mg/kg lipid for other pesticide compounds. The average percentage recoveries were greater than 95% for PCB congeners and ranged from 90% to 103% for pesticides. The between-day precision ranged from 3.3% to 7% for PCB congeners and 5.5% to 14.2% for pesticides.
Statistical Analysis
The distribution of characteristics for cases and controls were compared using w 2 tests for categorical variables or the Student's t-test for continuous variables. A priori, we decided to exclude from the statistical analysis chemicals with nondetectable levels in more than 30% of the patients. For the chemicals included in the analysis, patients with nondetectable levels were assigned half the value of the detection limit, which is a method used in earlier studies and by other laboratories (Haldane, 1955; Sala et al., 1999; Baris et al., 2000) . These patients were always in the baseline (first tertile) group for the analysis. Total PCBs were calculated by adding the concentrations of all PCB organochlorines included in the analyses for each patient, and total pesticide levels were calculated by adding the concentrations of all pesticide chemicals included in the analyses. Distributions of organochlorines were positively skewed, so were log-transformed to improve normality, and geometric means (GM) and associated 95% confidence intervals (CI) were calculated.
To estimate prostate cancer risk associated with each substance, tertiles of organochlorine levels were created based on the distribution among both control groups, and unconditional logistic regression was conducted to produce odds ratios (ORs) and 95% CIs, controlling for age. In addition, of the many covariates measured in the questionnaire, those who were associated with prostate cancer risk at Po0.20 were further tested as potential confounders (physical activity as a teen, total pack-years of smoking, and alcohol consumption in the 2 years before survey completion). Physical activity was collected as participants' selfassessed intensity of activity (little, moderate, strenuous), total pack-years of smoking was calculated from the number of years each participant smoked and the average number of cigarettes per day smoked during that time period (on a continuous scale), and the alcohol intake score was calculated as the sum of the values for beer, wine, and liquor consumption ratings, for which zero reflected no consumption or less than 1 drink per week, one represented between 1 and 7 drinks per week, two represented between 8 and 21 drinks per week, and three represented 22 or more drinks per week.
Potential covariates were included as confounders if their deletion from the model changed the parameter estimate of the primary exposure by 10% or more (Rothman and Greenland, 1998) . For PCBs, confounding was assessed for total PCBs and this model was used for all PCB congeners.
These models included age, teenage physical activity, alcohol consumption, and pack-years of smoking as confounders. For pesticides, confounding was assessed for p,p'-DDE, and this model was used for all pesticides, which included age, teenage physical activity, alcohol consumption, and packyears of smoking. An additional 1 case and 11 controls were excluded from regression analyses because of missing confounder information, resulting in a sample size of 396 men (78 cases, 318 controls). Sensitivity analyses were also performed by comparing cases to only the urology control group, and to controls after those with BPH were excluded. All analyses were performed using SAS (version 9.1; SAS Institute, Cary, NC, USA).
Results
Table 1 provides summary descriptive information. Over 70% of cases had a Gleason score of 6 or 7. For both cases and controls, more patients were born in Canada than in other countries, were of British ancestry as opposed to other ancestries, were married, were not currently smoking at the time of participation, did not have a first-degree relative with prostate or breast cancer, and did not have a vasectomy. Most cases and controls had low-to-moderate levels of occupational physical activity (P ¼ 0.005 for cases, Po0.001 for controls) compared with high levels. Comparing cases to controls, the only variable that significantly differed was ''physical activity as a teen,'' in which a higher proportion of cases than controls reported moderate or strenuous physical activity between the ages of 13 and 19 years (P ¼ 0.01).
Of the 27 organochlorines measured, more than 70% of patients had detectable levels of nine PCBs and seven pesticides. Excluded from the analysis on the basis of 30% or more patients with non-detectable levels were five PCB congeners (PCB28, PCB52, PCB101, PCB105, and PCB128), as well as aldrin, a-chlordane, g-chlordane, cis-nonachlor, dieldrin, and heptachlorepoxide. GMs for organochlorines by case-control status are presented in Table 2 . Among controls, the compounds with the highest concentrations were p,p'-DDE and total PCBs, and among PCB congeners, 153, 180, and 138 had the highest levels. GMs for PCB congeners, total PCBs, and p,p'-DDE were slightly lower for cases than controls, whereas levels of p,p'-DDT and other pesticides were virtually equal. Statistically significant differences were not found for any of the PCBs or pesticides.
Risk estimates for the associations between PCB congener tertiles and prostate cancer risk are presented in Table 3 , adjusted for age, total plasma lipid level, teenage physical activity, alcohol consumption, and pack-years of smoking. ORs were consistently below 1.0 for total PCBs and most levels of PCB congeners, excluding the intermediate levels of Sensitivity analyses show that results were consistent when the controls are confined to only urology controls, although the ORs were slightly higher than in the analysis with all controls included (Tables 5 and 6 ). When controls with BPH were excluded from analysis (51.1% of the biopsy controls and 2.3% of the urology controls), resulting ORs were slightly higher but remained statistically insignificant (not shown), and when controls with prostatitis were excluded (9.6% of biopsy and 23.1% of urology controls), results did not change (not shown). Finally, cases with high Gleason score (Z7, n ¼ 40) were compared with 295 controls, and cases with low grade (score r6, n ¼ 32) were compared with controls, with regression analyses conducted per 10 mg/kg of lipid increase in organochlorine concentration (not shown), and results remained insiginificant.
Discussion
Plasma levels of organochlorines are not associated with prostate cancer risk in this study. Although this is a small study, it is of very high quality in terms of excellent exposure assessment where organochlorines were measured in blood samples using a sensitive assay. The range of exposure variability afforded increased statistical power to detect risk if it existed.
Seventy percent of patients were found to have organochlorine levels above the limit of detection for 16 of the 27 organochlorines measured. The levels of these oganochlorines among controls were similar to those among women in the same geographical region (Aronson et al., 2000; Demers et al., 2002) . In this study, the levels of p, p'-DDE were higher than all other pesticides measured, at up to approximately 50 times higher than other measured contaminants, and PCB 153 had the highest levels among the PCB congeners.
A methodological advantage of this study is that as both cases and controls were PSA and DRE screened, the results are unlikely to be affected by selection bias. Men undergoing PSA screening are potentially more health conscious than those not getting screened (Richardson et al., 2007) , and selecting controls that have been screened allows for a control group free of PSA-selection bias (Kristal and Cohen, 2000) . Furthermore, most patients resided in the same area and all visited the same urologists in the same hospital. Cases and biopsy controls have also undergone the same diagnostic procedures, all cases were incident and histologically confirmed, and it is unlikely that there is latent carcinoma among controls. Information bias or differential recall bias was also likely to be minimized by the study design as blood was the primary exposure medium. We also excluded participants who had taken hormone-related medications and those with PIN, a known precursor of prostate cancer. Among the biopsy controls, diagnoses are BPH (53%), prostatitis/inflammation (24%), and gland atrophy (23%), and all of these conditions except prostatitis (Dennis et al., 2002) are not associated with increased risk for prostate cancer (DeMarzo et al., 1999) . A concern may be the high prevalence among controls of BPH, a common condition among older men. The etiology of BPH is poorly understood, and it is possible that this condition shares some etiological factors with prostate cancer. However, most agree that BPH is not a precursor to cancer, primarily because the two diseases occur in different parts of the prostate (Guess, 2001) . Although over 30% of our Similarly, although 24% had prostatitis conditions among biopsy controls (and 13% among urology controls), conclusions did not change when these patients were excluded.
Urology controls may better represent the exposure profile of the base population from which the cases derive. However, the two control groups have very similar characteristics, and risk estimates are similar with each control group. Although these controls involve some sacrifice of generalizability, the highest scientific validity possible is achieved because they are known to be free of prostate cancer. The clinic controls in this study represent an advantage over earlier studies that strengthens the validity of our conclusions.
Limitations include the small sample size resulting in low power and relatively wide CIs, preventing us from ruling out weak associations between the organochlorines measured and prostate cancer risk. This study is also limited in reflecting biologically relevant exposures, if the cumulative organochlorine levels measured in the plasma do not accurately represent the biologically effective levels in the relevant time window. The half-life of PCBs and p,p'-DDE range from 5 to 25 years (Smith, 1991; Wolff et al., 2000) , and 10 to 50 years for p,p'-DDT (Miller and Sharpe, 1998; Turusov et al., 2002) . Although age was correlated with most organochlorines, different organochlorine compounds persist for different periods of time and not all are long-lasting (Wolff et al., 2000) . For example, a prospective cohort study by Cohn et al. (2007) found that exposure to DDT before the age of 14 years was associated with a five-fold increase in breast cancer risk after the age of 50 years, whereas exposure after 14 years of age did not lead to a significantly increased risk. If endocrine disruptors such as DDT increase breast and prostate cancer risks through similar mechanisms, it is possible that measuring this exposure at the time of diagnosis does not accurately reflect the biologically active exposure levels. Several of these chemicals typically occur as mixtures, particularly PCBs. Organochlorines were treated as separate entities in this study to help identify whether specific organochlorines are associated with prostate cancer risk, while possible associations related to mixtures have not been assessed. PCB congeners with the highest potential estrogenicity are the most quickly metabolized, so would not be present in the blood to the same extent as other more slowly metabolized compounds (Wolff et al., 1997) .
There is epidemiological evidence to both support and refute the hypothesis that exposure to organochlorines and other environmental compounds acting as weak estrogens or anti-androgens might cause endocrine modulation, as well as produce a variety of adverse effects including potential prostate cancer (Wilkinson et al., 1997; Golden et al., 1998; Miller and Sharpe, 1998; Sonnenschein and Soto, 1998; Parent and Siemiatycki, 2001; Zafar and Terris, 2001 ).
Researchers of a meta-analysis posited that positive associations between prostate cancer and farming were likely attributed to exposure to hormonally active agricultural chemicals (Keller-Byrne et al., 1997) . Demers et al. (2002) suggested that exposure to dioxin-like PCBs might alter the metabolic pathways involved in biotransformation of both mono-ortho PCBs and estrogens, and these could be related to increased breast cancer risk (Demers et al., 2002) . Results from an in vitro study found that 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD) and correlated compounds mediated endocrine functions by enhancing ligand metabolism, adjusting hormone synthesis, reducing regulating receptor levels, and interfering with gene signal-transduction pathways (Jana et al., 1999) . It has also been shown that some organochlorine chemicals interact with the human androgen receptor in vitro as agonists, antagonists, or partial agonists/ antagonists (Schrader and Cooke, 2000) . In altering the metabolism of xenobiotics and steroid hormones, it is postulated that these chemicals may increase cell division (Morris and Seifter, 1992; Davis et al., 1993; Tessier and Matsumura, 2001; Schaufler et al., 2002) . Until several more epidemiological studies providing direct evidence are conducted, controversy will exist concerning the risk of prostate cancer posed by organochlorines (Charlier and Plomteux, 2002) . As gene-environment interactions may contribute to prostate cancer risk, studies with biomarkers of exposure and measuring polymorphisms would be helpful in unraveling the nature of the proposed connection between PCBs, pesticides, and prostate cancer (Chen, 2001; Shields, 2006) . All ORs are adjusted for age, teenage physical activity, alcohol consumption, and pack-years of smoking.
